DOCSLIB.ORG

Is It Eye Or

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Is It Eye Or "'Is"'Is itit EyeEye oror Pee?'Pee?' ChallengesChallenges toto SampleSample PrepPrep andand AnalysisAnalysis inin VeterinaryVeterinary Forensics"Forensics" KennethKenneth PeckPeck TexasTexas VeterinaryVeterinary MedicalMedical DiagnosticDiagnostic LaboratoryLaboratory CollegeCollege Station,Station, TXTX AnimalAnimal DrugDrug TestingTesting HighlyHighly DiverseDiverse SampleSample TypesTypes andand situationssituations –– RacingRacing SamplesSamples UseUse thethe smallestsmallest amountamount ofof aa drugdrug toto changechange performanceperformance –– LivestockLivestock ShowShow AnimalsAnimals DetectDetect drugsdrugs includingincluding growthgrowth promoterspromoters inin numerousnumerous speciesspecies withwith differentdifferent FDAFDA andand USDAUSDA requirements.requirements. FoodFood safetysafety requirementsrequirements –– PrePre--purchasepurchase drugdrug screens,screens, animalanimal poisoningspoisonings andand productproduct tampering.tampering. DrugDrug DiversityDiversity Aspirin,Aspirin, caffeine,caffeine, coughcough syrupssyrups NarcoticsNarcotics inin smallsmall dosesdoses actact asas stimulantsstimulants inin horses,horses, catscats andand bears.bears. AntibioticsAntibiotics andand foodfood safetysafety (drug(drug residues)residues) TranquilizersTranquilizers andand sedativessedatives BronchodilatorsBronchodilators GrowthGrowth promoterspromoters BetaBeta AgonistsAgonists BronchodilatorBronchodilator andand GrowthGrowth PromoterPromoter –– ClenbuterolClenbuterol –– AlbuterolAlbuterol –– TerbutalineTerbutaline –– PirbuterolPirbuterol –– ProcaterolProcaterol –– RactopamineRactopamine PayLeanPayLean (Porcine(Porcine andand Bovine)Bovine) –– ZilpaterolZilpaterol ZilMaxZilMax (Bovine(Bovine restricted)restricted) SampleSample TypeType andand TargetTarget AnalysisAnalysis HorseHorse RacingRacing –– Urine/Blood.Urine/Blood. RelativeRelative shortshort term.term. UsedUsed forfor thethe Bronchodilator/Bronchodilator/ cardiovascularcardiovascular effects.effects. HorseHorse urineurine isis veryvery unique.unique. HasHas thethe consistencyconsistency ofof warmwarm honeyhoney oror molasses.molasses. RequiresRequires largelarge porepore andand fritsfrits inin solidsolid phasephase andand MIPMIP extractions.extractions. DilutionDilution doesdoes notnot alwaysalways solvesolve thethe problemproblem SampleSample TypeType andand TargetTarget AnalysisAnalysis LivestockLivestock ShowsShows –– UrineUrine thethe routineroutine samplesample forfor bronchodilatorbronchodilator use.use. SuitableSuitable forfor solidsolid phasephase andand MIPMIP use.use. RetinaRetina harvestedharvested postpost slaughterslaughter forfor growthgrowth promoterpromoter use.use. Muscle/Liver/KidneyMuscle/Liver/Kidney LowLow drugdrug concentrations/Tissueconcentrations/Tissue manipulationmanipulation HorseHorse UrineUrine BetaBeta AgonistAgonist MIPMIP andand thethe NonNon-- IdealIdeal SampleSample Horse Urine. Very viscous/ Diluted 1:10 typically only 20% of the sample will successfully load on the column. Alternative approach. – Activate the column – Using a blunt probe (straighten paper clip) Recover/transfer the packing material. – Standard sample prep (internal standard) with ammonium acetate and adjust pH. Centrifuge sample and decant – Add MIP packing material, Allow binding by inversion – Centrifuge and decant or aspirate leaving the packing material – Transfer the packing material into a centrifugal filter. – Wash/elute with appropriate buffers/solvents using centrifugation RetinaRetina SeparateSeparate retinaretina fromfrom conjunctiva/scleraconjunctiva/sclera ofof eye.eye. HomogenizeHomogenize ProteaseProtease DigestDigest BetaBeta--GlucuronidaseGlucuronidase // SulfataseSulfatase AdditionAddition ofof acetateacetate bufferbuffer andand pHpH CentrifugationCentrifugation andand suitablesuitable forfor MIPMIP LowLow recoveryrecovery isis routinelyroutinely seen.seen. AlternativeAlternative TissueTissue SampleSample PrepPrep AfterAfter homogenationhomogenation // digestiondigestion // hydrolysishydrolysis AdjustAdjust pHpH toto approximatelyapproximately 1010 ExtractExtract withwith organicorganic solventsolvent 33 timestimes forfor highhigh recovery.recovery. ThisThis samplesample hashas highhigh backgroundbackground andand ionion-- suppression.suppression. ReconstituteReconstitute inin 2525 mMmM ammoniumammonium acetateacetate MIPMIP recoveriesrecoveries veryvery highhigh withwith lowlow backgroundbackground andand ionion--supression.supression. pH profile Zilpaterol 80 R 70 E 60 C 50 O V 40 E 30 R 20 Y 10 0 468101214 pH SolventSolvent ProfileProfile ofof ZilpaterolZilpaterol %% RecoveryRecovery pH Benzene Chloro- Methylene Ethyl Hexanes MTBE Pet Butanol Chloride Acetate Ether pH 22 9 48 87 0 61 1 11 PH 1 1 1 3 0 6 0 6 DetectionDetection GC/MSGC/MS (TMS(TMS derivative)derivative) –– ModerateModerate sensitivitysensitivity HPLCHPLC ColumnColumn TypeType –– CC--1818 columnscolumns givegive poorpoor resolution/retentionresolution/retention –– PhenylPhenyl--HexylHexyl excellentexcellent chromatographychromatography LC/MSLC/MS –– IonIon suppressionsuppression withwith urineurine andand tissues.tissues. Compound Mass Ion Fragmentor Prod Ion Collision Energy Rel Abundance Albuterol 239.15 240.2 95 148.1 16 100 77.1 60 25 222.1 4 15 51.1 104 9 Bitolterol 461.22 462.2 135 119.1 29 100 91.1 81 65 65.1 125 42 388.1 13 46 Clenbuterol 276.08 277.1 95 132.1 28 15 168 32 100 140 56 58 104.1 72 5 Fenoterol 303.15 304.2 110 107.1 33 100 77.1 77 37 51.1 117 14 135.1 17 83 Pirbuterol 240.15 241.2 110 167 13 100 185.1 9 51 94.1 49 65 149 21 83 Procaterol 290.16 291.2 110 273.2 8 100 162 28 32 77.1 88 2 174 36 4 Ractopamine 301.17 302.2 104 107 36 78 121 24 58 164.1 12 100 284.2 8 70 Terbutaline 225.14 226.1 94 107 42 99 77.1 42 68 125 42 96 152.1 42 100 Zilpaterol 261.15 262.2 105 185.1 24 100 157.1 36 30 244.1 8 78 130.1 52 32 ChromatographyChromatography C-18 3u 4x150 mm Phenyl-Hexyl 3u 4x150 mm CLENBUTEROL ZILPATEROL PROCATEROL ALBUTEROL ZilpaterolZilpaterol RetinaRetina PositivePositive Using combination of liq/liq and MIP extractions. High recovery with low background and low ion suppression SpecialSpecial ThanksThanks toto –– JimJim BrownBrown –– AndreAndre SalazarSalazar –– BrandyBrandy JessenJessen –– MarshaMarsha FarrarFarrar –– SylviaSylvia VegaVega –– ValsaValsa PhilipPhilip.
Load more

Recommended publications
  • Spirometry Protocol and Software Training Handout
    SPIROMETRY PROTOCOL AND SOFTWARE TRAINING HANDOUT Spirometry Protocol Key Points in Performing Spirometry ▪ Always demonstrate the maneuver ▪ Prompt the participant to BLAST out the air ▪ Continue by having the participant PUSH out the air ▪ Continue until the balloon bursts or at least six seconds Getting ready to do Spirometry Subjects will be instructed to not use any bronchodilator medicines for at least 4 hours prior to the appointment (in the case of salmeterol [Serevent] or Fomoterol (foradil)or Tritoprium (Spiriva) avoid for 12 hours prior to the test). Bronchodilator medicines include: Short acting bronchodilators Albuterol (ventolin, proventil, airet, volmax tablet) Levalbuterol (xopenex) Metaproterenol (alupent) Pirbuterol (maxair) Terbutaline (brethaire, brethine, bricanyl) Isoetharine (bronkosol) Ipratropium (atrovent) Ipratropium and albuterol combination (Combivent) Isoproteranol (isuprel) Primatine 1 CHW Educational Protocols – Spirometry Protocol and Software Training Handout Bitolterol (tornalate) Long acting bronchodilator Salmeterol (serevent) Fomoterol (foradil) Tritoprium (Spiriva) Bronchodilators should be avoided because they can affect the spirometry results. If the patient is having symptoms from asthma and needs to use the medicine, ask that the medicine be used 4 hours before the visit, so that the next dose is due during the visit. Patients can then do the spirometry and then the patient can take the medicine after the test is completed. When scheduling the follow-up spirometry visit, if at all possible, try to make the visit at the same time as the initial baseline visit. 1. Preparing the Computer 1. Check to see if the time and date on the lower right hand corner is current. If the date and time is NOT, the spirometer will NOT sync with the computer or the Easy One software.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Β2 Adrenergic Agonist Suppresses Eosinophil-Induced Epithelial-To- Mesenchymal Transition of Bronchial Epithelial Cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N
    Kainuma et al. Respiratory Research (2017) 18:79 DOI 10.1186/s12931-017-0563-4 RESEARCH Open Access β2 adrenergic agonist suppresses eosinophil-induced epithelial-to- mesenchymal transition of bronchial epithelial cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N. D’Alessandro-Gabazza2, Masaaki Toda2, Taro Yasuma2, Kota Nishihama2, Hajime Fujimoto3, Yu Kuwabara1,2, Koa Hosoki1,2, Mizuho Nagao1, Takao Fujisawa1 and Esteban C. Gabazza2* Abstract Background: Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial- mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full β2 adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils. Methods: Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line. Results: Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific β2-adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol. Conclusions: Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases.
    [Show full text]
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]
  • Clenbuterol Elisa Kit Instructions Product #101219 & 101216 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology CLENBUTEROL ELISA KIT INSTRUCTIONS PRODUCT #101219 & 101216 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Clenbuterol and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Clenbuterol ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug- enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T (51) International Patent Classification: Novartis Pharmaceuticals Corporation, 150 Industrial A61K 9/00 (2006.01) A61K 31/00 (2006.01) Road, San Carlos, California 94070 (US). A61K 9/16 (2006.01) (74) Agent: MAZZA, Michael; Novartis Vaccines and Dia (21) International Application Number: gnostics, Inc., 4560 Horton Street, Emeryville, California PCT/IB2014/059632 94608 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 11 March 2014 ( 11.03.2014) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/784,865 14 March 2013 (14.03.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant (for all designated States except US) : NO¬ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (CH).
    [Show full text]
  • For the Durable Medical Equipment Regional Contractors (Dmercs) Initiated a Revision to the Local Coverage Determination (LCD) for Nebulizers
    AMERICAN ASSOCIATION FOR HOMECARE Via Hand Delivery January 19, 2007 Leslie V. Norwalk, Esq. Acting Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Room 445-G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201 http://www.cms.hhs.gov/eRulemaking Re: National Coverage Analysis for Nebulized Beta Adrenergic Therapy for Lung Diseases (CAG - 00354N) Dear Ms. Norwalk: The American Association for Homecare (AAHomecare) submits the following comments on the Centers for Medicare and Medicaid Services' (CMS') national coverage analysis (NCA) for nebulized beta adrenergic agonist therapy for lung disease. AAHomecare is the only national association representing every line of service within the homecare community. AAHomecare members include home health agencies and suppliers and manufacturers of DME, prosthetics, orthotics, and supplies (collectively "DMEPOS"), rehab and assistive technologies, and pharmacies that provide infusion and inhalation drug therapies to patients in their homes. Our membership reflects a cross-section of the homecare community, including national, regional, and local providers and suppliers. AAHomecare and its members are committed to advancing the value and practice of quality health care services at home. I. BACKGROUND As you are aware, coverage for outpatient drugs under Medicare Part B is limited to a very small number of drugs. With respect to respiratory medications, Medicare covered inhalation drugs used with a nebulizer under the premise that the drug was a supply necessary to accomplish the l therapeutic objective of the nebulizer. Medicare pays for the nebulizer, the drug, and any necessary supplies. Inhalation drugs differ significantly from other outpatient drugs that are self- administered because they require an array of professional and administrative services, including delivery, education, oversight, and monitoring to ensure that the drug therapy is administered safely and effectively in the home.
    [Show full text]
  • Salmeterol Versus Slow-Release Theophylline Combined with Ketotifen in Nocturnal Asthma: a Multicentre Trial
    Eur Resplr J 1992, 5, 1197-1200 Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial J.F. Muir*, L. Bertin**, D Georges**, French Multicentre Study Group Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal • Service de Pneumologie, Hopital de asthma: a multicentre trial. J.F. Muir, L. Bertin, D. Georges, French Multicentre Bois Guillaume, Boisguillaume, France Study Group. • • Laboratoires Glaxo, France. ABSTRACT: We wished to assess the efficacy of inhaled salmeterol (SML; 50 Correspondence: L. Bertin 1-1g b.i.d.) compared to a combination of slow-release theophylline and ketotlfen Laboratoires Glaxo p.o. (TK; T 300 mg + K 1 mg b.i.d.) for the treatment of nocturnal asthma. 43, rue Vineuse - B.P. 166-16 Ninety six patients with nocturnal asthma, (forced expiratory volume in one sec­ F-75764 Paris Cedex 16 ) ond (FEV1 60-90% of predicted value, reversibility :z:lS%, at least two noc­ France tur nal awakenings per week) were eligible for a multicentre, double-blind, double-dummy cross-over study (14-day run-in, two successive 28-day treatment Keywords: ketotifen periods), Efficacy was assessed as success/failure, success being defined as the nocturnal asthma complete disappearance of nocturnal symptoms/awakenings during the last week salmeterol of each treatment period. theophylline There was a statistically significant difference between SML and TK for this Received: January 30 1992 criterion: 46% and 39% success with SML during periods I (first 28-day pe­ Accepted after revision August 2 1992 riod) and li (following the cross-over), compared to only 15% and 26% with TK, respectively (p<O.Ol).
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients
    Journal of Clinical Medicine Review Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients Yoshiaki Minakata * and Seigo Sasaki Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama 644-0044, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-738-22-3256 Received: 7 September 2020; Accepted: 27 October 2020; Published: 29 October 2020 Abstract: Increasing physical activity (PA) in patients with chronic obstructive pulmonary disease (COPD) is an important issue, however, the effect of bronchodilators on PA is still controversial. The indicators of PA, as measured by an accelerometer, can easily fluctuate based on several factors, which might cause inconsistent results. In this review, we listed the indicators of PA and the factors influencing the reproducibility of indicators of PA, and reviewed reports in which the effects of bronchodilators on PA were evaluated by an accelerometer. Then, we investigated the association between the processing of influencing factors and the effectiveness of bronchodilators for improving the PA of COPD patients. Fifteen reports were extracted using the PubMed database. In all seven reports in which adjustment was performed for at least two of four influencing factors (non-wear time, data from days with special behavior, environmental factors, and number of valid days required to obtain reproducible data), bronchodilators showed beneficial effects on PA. No adjustment was made for any of these factors in any of the four bronchodilator-ineffective reports. This suggests that the processing of influencing factors to secure reproducibility might affect the results regarding the effectiveness of bronchodilators for improving PA in COPD patients.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0047336A1 Yang Et Al
    US 20090047336A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0047336A1 Yang et al. (43) Pub. Date: Feb. 19, 2009 (54) NOVEL FORMULATION OF DEHYDRATED Publication Classification LPID VESICLES FOR CONTROLLED (51) Int. Cl. RELEASE OF ACTIVE PHARMACEUTICAL A63/37 (2006.01) INGREDIENT VLANHALATION A6II 47/06 (2006.01) A 6LX 9/27 (2006.01) (75) Inventors: Zhijun Yang, Kowloon (CN); A6IR 9/14 (2006.01) Wenhua Huang, Kowloon (CN); A6IP II/00 (2006.01) Chi Sun Wong, Hong Kong (CN); A6IP II/06 (2006.01) Zhongzhen Zhao, Kowloon (CN) (52) U.S. Cl. .......... 424/450; 424/489: 514/653: 514/772 Correspondence Address: (57) ABSTRACT LEYDIG VOIT & MAYER, LTD A new formulation of dehydrated lipid vesicles employs a 700 THIRTEENTH ST. NW, SUITE 300 vesicle preserver and permits the control of release and deliv WASHINGTON, DC 20005-3960 (US) ery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical (73) Assignee: HONG KONG BAPTIST formulation provides controlled release of the active pharma UNIVERSITY, Kowloon (CN) ceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical (21) Appl. No.: 11/840,537 administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, (22) Filed: Aug. 17, 2007 reduced systemic side effects, reduced toxicity. S Patent Application Publication US 2009/0047336A1 60 T. 50 40 30 20 O O Time (hours) --DOPC+1% gly cerin w8m DOTAP+1% glycerin FIG. 2 US 2009/0047336A1 Feb. 19, 2009 NOVEL FORMULATION OF DEHYDRATED blood pressure.
    [Show full text]